P1
Immunological predictive factors for treatment response during bulevirtide therapy in HBV-HDV coinfected patients.
C. Taibi, E. Cimini, G. Grassi, A. Caioli, A. Rianda, F. Cristofanelli, S. Pauciullo, V. Zulian, A.R. Garbuglia, A.M. Geretti, E. Biliotti, G. D’Offizi
P2
Discontinuation of bulevirtide monotherapy in patients with chronic hepatitis D: A prospective multicenter study (D-SOLVE BUL-STOP)
H. Wedemeyer, J. Kahlhöfer, E. Degasperi, K. Sprinzl, C. Zöllner, S. Nkongolo, D. Sambarino, K. Port, J. Schulze zur Wiesch, B. Bremer, K. Steppich, A. Kraft, H. Kefalakes, A. Großhennig, R. Ringlstetter, L. Sandmann, P Lampertico, K. Deterding, for the D
P3
Integrated efficacy analysis by HDV and HBV genotypes in patients with chronic hepatitis delta receiving bulevirtide
T. Stepanova, S. Aleman, T. Asselah, P. Bogomolov, M. Brunetto, V. Chulanov, G.S. Gherlan, P. Lampertico, V. Morozov, O. Sagalova, A. Streinu-Cercel, F. Zoulim, A. Lichtman, M. Li, H. Mo, D. Manuilov, H. Wedemeyer
P4
Long-term treatment with bulevirtide 2 mg improves Fatigue Severity Scale scores in patients with chronic hepatitis delta virus: Results from an exploratory analysis of the Phase 3 MYR301 trial
M. Buti, H. Wedemeyer, S. Aleman, V. Chulanov, V. Morozov, O. Sagalova, T. Stepanova, R.G. Gish, S. Zeuzem, J. Schulze zur Wiesch, M. Cornberg, M.R. Brunetto, D. Manuilov, A. Lichtman, M. Rock, C. Kim, S. Pandey, B. Singh, P. Lampertico
P5
No impact of antidrug antibodies on the efficacy of bulevirtide in chronic hepatitis delta: Insights from a 96-week integrated analysis
P. Lampertico, S. Aleman, H. Wedemeyer, A. Streinu-Cercel, P. Bogomolov, V. Morozov, T. Stepanova, S. Lazar, M. Brunetto, V. Chulanov, G.S. Gherlan, O. Sagalova, R-C. Mercier, L. Caro, M. Li, A. Lichtman, D. Manuilov, T. Asselah, A. Blank, F. Zoulim, M. C
